Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme

Armstrong, MJ; Houlihan, DD; Rowe, IA; Clausen, Who; Elbrønd, B; Gough, S; Tomlinson, J W; Newsome, PN

doi:10.1016/s0140-6736(13)60460-2

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Údaje z registračných štúdií liraglutidu preukázali pokles aktivity hepatálnych enzýmov. V CT obraze došlo k zmierneniu steatózy [44]. Štúdia z Británie randomizovala 52 pacientov s NASH, v dvoch ramenách boli pacienti liečení liraglutidom a placebom počas 1 roka.…”

Section: Mimetiká Inkretínu a Liraglutidunclassified

Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms

Rác¹,

Skladaný²

2018

Vnitř Lék

View full text Add to dashboard Cite

SúhrnObezita dosahuje rozmery globálnej epidémie. Priamo prispieva k nárastu prevalencie systémových ochorení asociovaných s obezitou. Obezita a nadváha globálne spôsobia ročne 3,5 miliónov úmrtí [1]. Nealkoholová tuková choroba pečene sa stala najčastejším chronickým pečeňovým ochorením v rozvinutých krajinách a je považovaná za pečeňovú manifestáciu metabolického syndrómu. Rozsah a bremeno choroby stále rastie a dosahuje epidemické rozmery práve pre svoju úzku spojitosť s epidémiou obezity a diabetes mellitus 2. typu. Postihuje 30 % dospelej populácie [2]. Alarmujúci je nárast prevalencie u detí a mladistvých. V skupine pacientov s vysokým kardiometabolickým rizikom je prevalencia NAFLD významne vyššia. Prevalencia u obéznych pacientov dosahuje 75-92 %, prevalencia u diabetikov sa pohybuje medzi 60-70 % [3]. Významná časť pacientov s NAFLD bude trpieť progresívnou formou ochorenia -nealkoholovou steatohepatitídou (NASH), ktorá sa spája s rozvojom pokročilej pečeňovej fibrózy, cirhózy a jej komplikáciami. Rastúca prevalencia NASH v blízkej budúcnosti privedie do štádia pokročilej choroby pečene obrovskú kohortu našich pacientov. Ak sa nepodarí zvrátiť nepriaznivý epidemiologický trend, tak v nasledujúcej dekáde bude najčastejším dôvodom transplantácie pečene práve NASH. Neustále rastúci trend možno pozorovať v náraste počtu prípadov hepatocelulárneho karcinómu v kauzálnej súvislosti s NASH [4]. Liečba založená na ovplyvnení kľúčových patogenetických mechanizmov by mohla zmeniť individuálnu budúcnosť chorých, ale aj globálne bremeno vyplývajúce z NASH. Kľúčovú rolu v budúcnosti budú zohrávať nové molekuly s protizápalovým a antifibrotickým efektom. Kľúčové slová: cirhóza pečene -inzulínová rezistencia -metabolický syndróm -NASH Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms SummaryObesity reaches the dimensions of the global epidemic. It directly contributes to an increase in the prevalence of systemic diseases associated with obesity. Obesity and overweight globally cause 3.5 million deaths annually [1]. Non-alcoholic fatty liver disease has become the most common chronic liver disease in developed countries and is considered to be a liver manifestation of metabolic syndrome. The extent and burden of the disease are increasing and reaching epidemic proportions because of its close association with the epidemic of obesity and diabetes mellitus type [2]. It affects 30 % of the adult population [2]. There is an alarming increase in prevalence among children and adolescents. However, in the group of patients with high cardiometabolic risk, we can see a significantly higher prevalence of NAFLD. Prevalence in obese patients is 75 -92 %, in diabetic patients prevalence is between 60 -70 % [3]. A significant proportion of patients with NAFLD will suffer from a progressive form of the disease -non-alcoholic steatohepatitis (NASH), which is associated with the development of advanced liver fibrosis, cirrhosis, and its complications. The growing prevalence...

show abstract

Section: Mimetiká Inkretínu a Liraglutidunclassified

Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms

Rác¹,

Skladaný²

2018

Vnitř Lék

View full text Add to dashboard Cite

show abstract

“…It is a long-acting GLP-1 analogue that has been licensed for glycaemic control in overweight patients with type 2 diabetes ( 12) and for the treatment of obesity. A large meta-analysis of patients with type 2 diabetes and elevated liver enzymes treated with liraglutide showed an improvement in liver biochemistry (22), whereas a pilot study demonstrated that treatment with liraglutide had a good safety profile and significantly improved liver function and histological features in NASH patients (23). An important recent multicentre, double-blinded, randomized, placebocontrolled trial assessed the safety and efficacy of liraglutide, in patients with NASH.…”

Section: Intestinal Hormones and Nafldmentioning

confidence: 99%

Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease

Koukias¹,

Buzzetti²,

Tsochatzis³

2017

Minerva Endocrinol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and has a complex pathophysiology with multiple pathways of development and progression implicated. Intestinal hormones regulate multiple biological functions and may play a role in the pathogenesis of non alcoholic fatty liver disease (NAFLD) by affecting food intake, body weight and insulin resistance. Bacterial products can affect the secretion of these hormones and thus have an effect on metabolism. Gut microbiota are normally involved in the intestinal energy harvest and their role has been increasingly been implicated in the pathogenesis of obesity and NAFLD. The intestinal hormone pathways as well as in the intestinal microbiota populations are potential therapeutic targets in the management of NAFLD. We review the evidence on the associations of the intestinal hormones and gut microbiota in the development, progression and treatment of NAFLD.

show abstract

“…Uma meta-análise de dados de 4.000 pacientes com DM2, mostrou que após vinte e seis semanas de tratamento com liraglutida houve uma melhora significativa na produção de enzimas hepáticas, se mostrando também um tratamento seguro e bem tolerado pelos pacientes (83). Considerado de uso clínico predominante, a liraglutida (Victoza ® ), demonstrou altos níveis de benefício glicêmico em estudos comparativos contra outros agonistas do receptor de GLP-1 (85)(86)(87)(88).…”

Section: Liraglutidaunclassified

Avaliação do tratamento com metformina e liraglutida em modelo de esteatose pancreática in vivo murino

Silva¹

View full text Add to dashboard Cite

pela oportunidade concedida, pelos ensinamentos e pelas boas conversas e risadas. Ao Prof. Dr. Bruno Caramelli pelo profissionalismo e por ter me acolhido em seu serviço, possibilitado que eu realizasse este trabalho. À Dra. Marluce Mantovani pela co-orientação, ensinamentos, ajuda inigualável e parceria do começo ao fim deste trabalho e por sua amizade. À Zizi Mendonça pela inestimável ajuda na realização de experimentos e companheirismo, sempre disposta a ajudar. À Prof. Dra. Mari Sogayar que me deu a primeira oportunidade, abriu as portas para mim, possibilitando o início dessa jornada. À instituição de fomento CAPES (bolsa de mestrado, processo 8888.7.372065/2019-00), pelo apoio financeiro durante a realização deste trabalho. À todos do grupo NUCEL e aqueles que, direta ou indiretamente, contribuíram para a realização deste trabalho. NORMALIZAÇÃO ADOTADAEsta tese está de acordo com as seguintes normas, em vigor no momento desta publicação:

show abstract

Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme

Cited by 4 publications

References 0 publications

Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms

Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms

Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease

Avaliação do tratamento com metformina e liraglutida em modelo de esteatose pancreática in vivo murino

Contact Info

Product

Resources

About